AAS
AMLX icon

Ameritas Advisory Services’s Amylyx Pharmaceuticals AMLX Stock Holding History

Ameritas Advisory Services’s Portfolio AMLX Stock Details AMLX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-3
Closed -$42 – 1951
2026
Q1 		$42 Buy
+3
New +$42 ﹤0.01% 1067

Other funds holding AMLX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return
CC
Commodore Capital New York $1.68B AUM 375.52% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
SVCM
Saturn V Capital Management Austin, Texas $697M AUM 628.57% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return

Ameritas Advisory Services's AMLX Position: Q2 2026 in Review

Ameritas Advisory Services sold out of Amylyx Pharmaceuticals (AMLX) in Q2 2026, closing a stake of 3 shares — an estimated $42 sold.

Ameritas Advisory Services first reported a position in AMLX in Q1 2026 and held it in 1 quarter. The position peaked at $42 in Q1 2026. 206 funds tracked by Wall St. Rank hold AMLX as of Q2 2026.

  • Ameritas Advisory Services reported no remaining Amylyx Pharmaceuticals position as of Q2 2026 after selling out during the quarter.
  • Ameritas Advisory Services sold 3 Amylyx Pharmaceuticals shares in Q2 2026, an estimated $42.
  • Ameritas Advisory Services first reported a position in Amylyx Pharmaceuticals in Q1 2026 and held it in 1 quarter.
  • Ameritas Advisory Services's Amylyx Pharmaceuticals position peaked at $42 in Q1 2026.
  • 206 funds tracked by Wall St. Rank held Amylyx Pharmaceuticals as of Q2 2026.

Based on Ameritas Advisory Services's 13F filing for Q2 2026, filed 14 Aug 2026.